Uwe Weisner

April 12, 2021

As General Manager Corporate Intellectual Property at Volkswagen AG in Wolfsburg, Germany, Uwe is responsible for filing, prosecuting, licensing and enforcing Volkswagen’s Patents, Trademarks, Design Rights, Internet-Domains and defending against third party IP claims. In addition, he is responsible for standardization. Prior, Uwe served more than 15 years as a Patent Manager for Volkswagen AG and Audi AG, also located in Germany. Further functions: Chairman of the IP Committee of VDA (German Association of Automotive Industry), Board Member of the IP Committee of BDI (Association of German Industries) and Board Member of VPP (Association of Industry Patent Professionals in Germany). From 2010 to 2017 Lecturer at the Technical University of Braunschweig for “Business Practice of Intellectual Property.”

Don’t Tax Invention: The Risks of a Patent Tax

September 4, 2025

By Sujai Shivakumar and Chris Borges The Commerce Department is reportedly considering a novel revenue-raising idea to address the national debt: a “patent tax.” Under this proposal, patent holders would be required to pay the federal government between 1 and 5 percent of their patents’ assessed value each year. While the

The United States Needs a National Standards Strategy

July 16, 2025

By Richard Taffet and Chris Borges Competition among nations for technological and economic leadership is intense, especially between the United States and the People’s Republic of China (PRC). The PRC has followed a decades-long, targeted strategy focused on leadership in critical and emerging technologies (CETs), and, according to some, it has

How Most-Favored Nation Policy Could Undermine U.S. Leadership

July 10, 2025

By Dr. Anne Pritchett The United States is the global leader in biopharmaceutical innovation. This leadership is built on the pillars of strong intellectual property protection, substantial investment in research and development (R&D), and a robust innovation ecosystem. These factors, combined with a market-based system that supports competitive drug pricing, encourage innovation and